Latest acute leukemia Stories
BERGEN, Norway, November 19, 2014 /PRNewswire/ -- BerGenBio AS, an oncology biopharmaceutical company, today announces that the US Food and Drug Administration (FDA) has
BERGEN, Norway, November 4, 2014 /PRNewswire/ -- BerGenBio AS ("BerGenBio" or the "Company"), an oncology biopharmaceutical company, today announces that the first patient
- Tosedostat Currently in Phase 2 Development for Patients with AML and MDS - SEATTLE, Oct. 27, 2014 /PRNewswire/ -- CTI BioPharma Corp.
- Preliminary study results show 27 of 30 pediatric and adult patients with relapsed/refractory (r/r) ALL (90%) experienced complete remissions with personalized cell therapy, CTL0191 EAST
University of Pennsylvania and Children's Hospital of Philadelphia Research Team Funded by LLS for More Than 22 Years Report Today in New England Journal of Medicine that 90 Percent of Patients Achieved
Expansion of Collaboration Enables Identification of Optimal Patient Profiles and Combination Strategies for APTO-253 SAN DIEGO, CA AND TORONTO, ON; PORTLAND, OR AND WHITE PLAINS, NY,
Lead Compound, Quizartinib, Will Further Build Daiichi Sankyo Oncology Pipeline TOKYO and SAN DIEGO, Sept. 28, 2014 /PRNewswire/ -- Daiichi Sankyo Company, Ltd.
Collaborative efforts with leading cancer centers to provide clinical test is supported CAMBRIDGE, Mass., Sept.
SAN DIEGO, Sept. 9, 2014 /PRNewswire/ -- MEI Pharma, Inc.
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.